Complete dosing for BEAM-103 Phase 1 trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 May 2026
- Due
- 30 Jun 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The ongoing Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE, is expected to complete dosing in the first half of 2026.”
What we found
Evidence strength A What the grades mean
Beam Therapeutics confirmed in its August 2026 filings that it had completed enrollment and dosing for the Phase 1 healthy volunteer clinical trial of BEAM-103.
-
A Beam Therapeutics Inc. 10-Q filed 2026-08-04
“We have completed enrollment and dosing in a Phase 1 healthy volunteer clinical trial of BEAM-103” ✓ confirmed on the page
Market reaction: the shares moved +3.7% against the S&P 500 over the three sessions around the disclosure (3 Aug 2026 to 6 Aug 2026). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- BEAM-103 Phase 1 trial dosing
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-BEAM-003334 · Corrections policy